Safety, tolerability, and pharmacokinetics of a 2 g subcutaneous dose of ceftriaxone as an alternative to intravenous delivery
Antimicrobial Agents and Chemotherapy · 2026
DOI: 10.1128/aac.01081-25 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2026. Verfasst von Henco Nel und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, Fiona Stanley Fremantle Hospitals Group, Murdoch, Western Australia, Australia. Hauptthemen laut MEDLINE: Ceftriaxone, Anti-Bacterial Agents. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Stan Perron Charitable Foundation, Medical Research Future Fund Investigator Grant.
Abstract (Originalsprache)
Subcutaneous delivery of antibiotics is a practical alternative to intravenous administration. Ceftriaxone is commonly used for a variety of infections with limited data on the safety and pharmacokinetics of a 2 g subcutaneous dose. This was a prospective, self-controlled cross-over study in 20 stable inpatients receiving ceftriaxone for their infection. Following an intravenous dose, participants received a single dose of 2 g subcutaneous ceftriaxone, in 50 mL normal saline via gravity feed. Capillary dried blood spots were collected at baseline, 1, 2, 4, 8, and 24 hours following the subcutaneous and intravenous doses. Pain scores and infusion site reactions (edema/erythema) were assessed. Ceftriaxone concentrations were measured using a validated liquid chromatography-tandem mass spectrometry assay. A population pharmacokinetic model was developed using nonlinear mixed-effects modeling. The highest median (interquartile range) pain score within the first 2 hours following infusion of a subcutaneous dose of 2 g ceftriaxone was 2.5 (1–4). All participants were pain-free 4 hours after the infusion. The estimated bioavailability was 95.7% (95% bootstrap interval 90.3–99.5). Compared with intravenous, subcutaneous administration resulted in lower peak and comparable trough concentrations. The probability of target attainment for free drug concentrations was similar to intravenous administration for most common infections in hospitalized patients. Subcutaneous administration of 2 g ceftriaxone is well tolerated and has a comparable pharmacokinetic profile relative to intravenous dosing in non-critically ill patients with severe infections. IMPORTANCE This prospective, self-controlled cross-over design study demonstrates that subcutaneous administration of 2 g ceftriaxone appears safe and well tolerated with a comparable pharmacokinetic profile relative to intravenous dosing in non-critically ill patients with severe infections. CLINICAL TRIALS This study was registered at ACTRN12624000692538 .
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Infectious Diseases, Fiona Stanley Fremantle Hospitals Group, Murdoch, Western Australia, Australia.
- Wesfarmers Centre of Vaccines and Infectious Diseases, Telethon Kids Institute, University of Western Australia, Perth, Western Australia, Australia.
- Pharmacy, School of Allied Health, The University of Western Australia, Perth, Western Australia, Australia.
- Institute for Paediatric Perioperative Excellence, The University of Western Australia, Perth, Western Australia, Australia.
- Centre for Optimisation of Medicines, School of Allied Health, University of Western Australia, Perth, Western Australia, Australia.
- Department of Pharmacy, Fiona Stanley Fremantle Hospitals Group, Murdoch, Western Australia, Australia.
ORCID-Profile: Henco Nel, Fionnuala Murray, Matthew Rawlins, Edward Raby, Sam Salman, Laurens Manning
Förderung
- Stan Perron Charitable Foundation
- Medical Research Future Fund Investigator Grant
Zitieren
APA
Nel, H., Murray, F., Yoo, O., Rawlins, M., Raby, E., Page-Sharp, M., Moore, B., Salman, S., & Manning, L. (2026). Safety, tolerability, and pharmacokinetics of a 2 g subcutaneous dose of ceftriaxone as an alternative to intravenous delivery. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.01081-25
Vancouver
Nel H, Murray F, Yoo O, Rawlins M, Raby E, Page-Sharp M, et al. Safety, tolerability, and pharmacokinetics of a 2 g subcutaneous dose of ceftriaxone as an alternative to intravenous delivery. Antimicrobial Agents and Chemotherapy. 2026. doi:10.1128/aac.01081-25
BibTeX
@article{Nel2026,
author = {Nel, Henco and Murray, Fionnuala and Yoo, Okhee and Rawlins, Matthew and Raby, Edward and Page-Sharp, Madhu and Moore, Brioni and Salman, Sam and Manning, Laurens},
title = {Safety, tolerability, and pharmacokinetics of a 2 g subcutaneous dose of ceftriaxone as an alternative to intravenous delivery},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2026},
doi = {10.1128/aac.01081-25}
}
EUVIMED